409 related articles for article (PubMed ID: 36853018)
1. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
[TBL] [Abstract][Full Text] [Related]
2. "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing.
Khalafallah AM; Huq S; Jimenez AE; Serra R; Bettegowda C; Mukherjee D
Neurosurgery; 2021 Feb; 88(3):477-486. PubMed ID: 32674143
[TBL] [Abstract][Full Text] [Related]
3. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients.
Zhao S; Wang Q; Ni K; Zhang P; Liu Y; Xie J; Ji W; Cheng C; Zhou Q
Front Immunol; 2023; 14():1263329. PubMed ID: 37727789
[TBL] [Abstract][Full Text] [Related]
4. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
Qazi MA; Vora P; Venugopal C; Sidhu SS; Moffat J; Swanton C; Singh SK
Ann Oncol; 2017 Jul; 28(7):1448-1456. PubMed ID: 28407030
[TBL] [Abstract][Full Text] [Related]
6. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
7. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
Xuan Z; Fang L; Zhang G; Zhang X; Jiang J; Wang K; Huang P
J Mol Neurosci; 2023 Jan; 73(1):1-14. PubMed ID: 36542317
[TBL] [Abstract][Full Text] [Related]
8. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
9. Expression Profiling of Primary and Recurrent Glioblastomas Reveals a Reduced Level of Pentraxin 3 in Recurrent Glioblastomas.
Petterson SA; Sørensen MD; Kristensen BW
J Neuropathol Exp Neurol; 2020 Sep; 79(9):975-985. PubMed ID: 32791527
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression.
Chen X; Chen Y; Chen X; Wei P; Lin Y; Wu Z; Lin Z; Kang D; Ding C
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166534. PubMed ID: 36057370
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
Front Immunol; 2020; 11():835. PubMed ID: 32457755
[TBL] [Abstract][Full Text] [Related]
12. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
13. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma heterogeneity at single cell resolution.
Eisenbarth D; Wang YA
Oncogene; 2023 Jun; 42(27):2155-2165. PubMed ID: 37277603
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Yeo AT; Rawal S; Delcuze B; Christofides A; Atayde A; Strauss L; Balaj L; Rogers VA; Uhlmann EJ; Varma H; Carter BS; Boussiotis VA; Charest A
Nat Immunol; 2022 Jun; 23(6):971-984. PubMed ID: 35624211
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs as Multifaceted Players in Glioblastoma Multiforme.
Mercatelli N; Galardi S; Ciafrè SA
Int Rev Cell Mol Biol; 2017; 333():269-323. PubMed ID: 28729027
[TBL] [Abstract][Full Text] [Related]
17. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
18. Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors.
Knudsen AM; Halle B; Cédile O; Burton M; Baun C; Thisgaard H; Anand A; Hubert C; Thomassen M; Michaelsen SR; Olsen BB; Dahlrot RH; Bjerkvig R; Lathia JD; Kristensen BW
Neuro Oncol; 2022 Jul; 24(7):1074-1087. PubMed ID: 34964899
[TBL] [Abstract][Full Text] [Related]
19. Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model.
Liu Y; Wu Z; Feng Y; Gao J; Wang B; Lian C; Diao B
Front Oncol; 2023; 13():1109037. PubMed ID: 37397378
[TBL] [Abstract][Full Text] [Related]
20. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.
Gill BJ; Pisapia DJ; Malone HR; Goldstein H; Lei L; Sonabend A; Yun J; Samanamud J; Sims JS; Banu M; Dovas A; Teich AF; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Sims PA; Canoll P
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12550-5. PubMed ID: 25114226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
